ArticleLeukemia & lymphoma2019

Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.

Paul J Hampel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.